{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Descriptive+Intervention&page=20", "query": { "intervention": "Descriptive Intervention", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 769, "total_pages": 77, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Descriptive+Intervention&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Descriptive+Intervention&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T15:45:42.202Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05433636", "title": "Mindful Waiting Room", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety State", "Depressive State", "Pain", "Nausea", "Fatigue", "Cancer" ], "interventions": [ { "name": "Body Scan", "type": "BEHAVIORAL" }, { "name": "Mindful Breathing", "type": "BEHAVIORAL" }, { "name": "Mindfulness of Discomfort", "type": "BEHAVIORAL" }, { "name": "Mindful Savoring", "type": "BEHAVIORAL" }, { "name": "Integrative Health Recording", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 305, "start_date": "2022-09-14", "completion_date": "2024-12-01", "has_results": false, "last_update_posted_date": "2024-02-06", "last_synced_at": "2026-10-27T15:45:42.202Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05433636" }, { "nct_id": "NCT06096844", "title": "Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Lung Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 304, "start_date": "2024-07-19", "completion_date": "2039-04-01", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-27T15:45:42.202Z", "location_count": 328, "location_summary": "Fayetteville, Arkansas • Fort Smith, Arkansas • Rogers, Arkansas + 257 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Dublin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06096844" }, { "nct_id": "NCT04121312", "title": "Engaging Patients in Weight Loss Tools", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Facilitation Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 33, "start_date": "2019-10-28", "completion_date": "2020-07-24", "has_results": false, "last_update_posted_date": "2024-01-16", "last_synced_at": "2026-10-27T15:45:42.202Z", "location_count": 2, "location_summary": "Gainesville, Florida • Jacksonville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04121312" }, { "nct_id": "NCT01503632", "title": "Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Behavioral Intervention", "type": "BEHAVIORAL" }, { "name": "Compliance Monitoring", "type": "BEHAVIORAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Standard Follow-Up Care", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 570, "start_date": "2012-02-21", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-27T15:45:42.202Z", "location_count": 100, "location_summary": "Birmingham, Alabama • Downey, California • Duarte, California + 76 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01503632" }, { "nct_id": "NCT07158749", "title": "Generalized and Domain-Specific Episodic Thinking for Smoking Cessation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cigarette Smoking Behavior" ], "interventions": [ { "name": "Episodic Future Thinking (EFT)", "type": "BEHAVIORAL" }, { "name": "Episodic Recent Thinking (ERT)", "type": "BEHAVIORAL" }, { "name": "Domain-specific episodic thinking", "type": "BEHAVIORAL" }, { "name": "Generalized episodic thinking", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Virginia Polytechnic Institute and State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 134, "start_date": "2026-09-25", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-27T15:45:42.202Z", "location_count": 1, "location_summary": "Roanoke, Virginia", "locations": [ { "city": "Roanoke", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07158749" }, { "nct_id": "NCT07064564", "title": "iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Opioid Use Disorder" ], "interventions": [ { "name": "Naltrexone implant, 14.4 grams", "type": "DRUG" }, { "name": "Naltrexone implant, 9.6 grams", "type": "DRUG" }, { "name": "Extended-release naltrexone injection, 380 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akyso Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 33, "start_date": "2026-07-25", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-27T15:45:42.202Z", "location_count": 1, "location_summary": "Millcreek, Utah", "locations": [ { "city": "Millcreek", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07064564" }, { "nct_id": "NCT04284787", "title": "BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Acute Myeloid Leukemia Post Cytotoxic Therapy", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 60, "start_date": "2021-02-16", "completion_date": "2027-01-30", "has_results": true, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-27T15:45:42.202Z", "location_count": 29, "location_summary": "Greenwich, Connecticut • Hartford, Connecticut • New Haven, Connecticut + 23 more", "locations": [ { "city": "Greenwich", "state": "Connecticut" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04284787" }, { "nct_id": "NCT05219838", "title": "Binding and Effects of Lu AG06466 in the Brain of Healthy Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Lu AG06466", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "MALE", "summary": "18 Years to 50 Years · Male only" }, "enrollment_count": 8, "start_date": "2022-01-18", "completion_date": "2022-08-29", "has_results": false, "last_update_posted_date": "2022-09-09", "last_synced_at": "2026-10-27T15:45:42.202Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05219838" }, { "nct_id": "NCT02828358", "title": "Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia of Ambiguous Lineage", "B Acute Lymphoblastic Leukemia", "Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Hydrocortisone Sodium Succinate", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "364 Days", "sex": "ALL", "summary": "Up to 364 Days" }, "enrollment_count": 78, "start_date": "2017-04-01", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-10-27T15:45:42.202Z", "location_count": 157, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 128 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02828358" }, { "nct_id": "NCT05090319", "title": "Micro-hematology Analyzer for Viral/Bacterial Description", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Infection Viral", "Infection, Bacterial" ], "interventions": [ { "name": "complete blood count", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "RizLab Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 200, "start_date": "2021-07-25", "completion_date": "2022-07-24", "has_results": false, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-10-27T15:45:42.202Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05090319" } ] }